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OBJECTIVES To evaluate in-hospital and long-term clinical outcomes in a large consecutive series of
patients undergoing percutaneous multivessel stent intervention.
BACKGROUND High restenosis and recurrent angina rates have limited the clinical outcomes of multivessel
coronary angioplasty before stents were available to improve angioplasty results.
METHODS We evaluated in-hospital and long-term clinical outcomes (death, Q-wave myocardial
infarction [MI], and repeat revascularization rates at one year) in 398 consecutive patients
treated with coronary stents in two (94% of patients) or three native arteries, compared to
1,941 patients undergoing stenting procedure in a single coronary artery between January 1,
1994 and August 29, 1997.
RESULTS Overall procedural success was obtained in 96% of patients with two- or three-vessel stenting
and in 97% of patients with single-vessel stent intervention (p 5 0.36). Procedural
complications were also similar (3.8% for multivessel versus 2.9% for single vessel, p 5 0.14).
During follow up, target lesion revascularization was 15% in multivessel and 16% in
single-vessel interventions (p 5 0.38), and repeat revascularization (calculated per treated
patient) was also similar for both groups (20% vs. 21%, p 5 0.73). There was no difference
in death (1.4% vs. 0.7%, p 5 0.26), and Q-wave MI (1.2% vs. 0%, p 5 0.02) was lower
following multivessel interventions. Overall cardiac event-free survival was similar for both
groups (p 5 0.52).
CONCLUSIONS Unlike previous conventional angioplasty experiences, multivessel stenting has (1) similar
in-hospital procedural success and major complication rates and (2) similar long-term (one
year) clinical outcomes compared with single-vessel stenting. Thus, stents may be a viable
therapeutic strategy in carefully selected patients with multivessel coronary disease. (J Am
Coll Cardiol 1999;33:420–6) © 1999 by the American College of Cardiology
Patients with multivessel coronary artery disease will often
be eligible for either catheter-based interventions or coro-
nary bypass surgery (coronary artery bypass graft [CABG]).
Before the stent era, multivessel angioplasty had less favor-
able procedural results compared with single-vessel inter-
ventions, and long-term outcomes were compromised by
the cumulative effect of restenosis (1). Consequently, the
results of randomized trials comparing angiopasty with
CABG differed markedly in the need for subsequent revas-
cularization procedures and angina relief, in favor of the
surgical approach (2–8). However, those randomized trials
were conducted before stents were available to improve
angiopasty results and reduce late restenosis (9–11). To
determine the clinical outcomes of patients with multivessel
disease treated by “contemporary” catheter-based strategy
and including stents when indicated, we evaluated proce-
dural success, major in-hospital complications and long-
term (one year) clinical events in a large consecutive series of
patients undergoing multivessel stenting compared with
coronary stent procedure in a single vessel.
METHODS
Patients and follow up. The patient cohort includes a
consecutive series of 2,339 patients (3,633 native coronary
lesions) in the Cardiology Research Foundation Angio-
plasty Database, treated with stents between January 1, 1994
and August 29, 1997. Patients were divided into two groups
according to the number of treated vessels (one vs. two or
three vessels) during a single intervention session. Among
patients with more than one treated vessel, the vast majority
(374 of 398 patients, 94%) underwent coronary intervention
in two vessels. Patients with two- or three-vessel interven-
tions underwent stent implantation in 672 of 995 (67%)
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lesions while nonstent procedures were performed in other
lesions. All indications for stent use (elective use to improve
acute procedural safety and reduce late clinical events,
provisional use to treat suboptimal primary device result or
urgent use to treat abrupt or threatened closure) are in-
cluded in this study. Baseline clinical demographics and
in-hospital complications were confirmed by independent
chart review. Patients with protected or unprotected left-
main intervention were excluded from analysis as well as
those patients with staged procedures.
All patients underwent preintervention and postinterven-
tion 12-lead electrocardiogram (ECG) to detect ischemic
changes, appearance of new pathologic Q-waves or both.
Blood samples were routinely acquired from all patients
every 8 h following the procedure for CK-MB enzyme
(normal values, 0 to 4 ng/ml). The diagnosis of non-Q
myocardial infarction (MI) was defined as CK-MB eleva-
tion $5 time normal values, in the absence of new patho-
logic Q-waves. Clinical outcomes at 1 year were obtained by
serial telephone interviews by research nurses and late
clinical events (death, Q-wave MI), target lesion revascu-
larization or any cardiac event (death, Q-wave MI, angio-
plasty or CABG) were adjudicated by accompanying source
documentation. In addition to target lesion revasculariza-
tion, repeat revascularization is also reported per patient (as
any repeat revascularization) and includes all target lesion
and target vessel revascularizations for single and multiple
vessel disease.
Stent techniques. Following the initial balloon angioplasty
or ablative procedure, coronary stents were implanted over a
0.0140 extra-support guidewire. All stents used during the
study period were included in the current analysis. Adjunct
high-pressure balloon inflation (14 to 16 atmospheres) was
added after initial stent deployment in all cases. Optimal
stent implantation was carefully monitored using an itera-
tive technique with prespecified intravascular ultrasound
end points in most cases. The prestent and poststent
anticoagulation regimens included aspirin (325 mg daily)
and ticlopidine (250 mg twice daily) for 1 month, and
additional low-molecular-weight heparin (for 2 weeks) in
particularly high risk subsets (e.g., thrombus-containing
lesions, and patients with $3 stents).
Angiographic analysis. We studied 1,920 lesions that were
available for complete quantitative and qualitative angio-
graphic analysis. Standard morphologic criteria were used
for the identification of lesion location, length, eccentricity,
calcification and ulceration. Quantitative angiographic anal-
ysis was performed using selected end-diastolic frames
demonstrating the stenosis in its most severe projection.
Using the contrast-filled guiding catheter as the calibration
standard, reference and lesion minimal lumen diameters
were determined before and after interventions.
Statistics. Continuous variables are presented as mean 6
1 SD. Categorical data are presented as percent frequency
and compared between groups using chi-square statistics.
Survival curves were calculated and displayed using a pro-
cedure (SASt LIFETEST). Wilcoxon statistics were used
for survival comparison between groups (one vessel versus
multivessel stents). The means of nominal values were
compared using the unpaired Student t test. A p value
,0.05 was accepted as statistically significant.
RESULTS
Baseline demographics. Table 1 lists the baseline charac-
teristics of all treated patients, divided according to the
number of arteries treated (1 vs. 2 or 3). Overall, patient
demographics were similar among groups, except for higher
prevalence of previous revascularization procedures (angio-
plasty and CABG), and recent (within seven days) MI in
the single-vessel intervention group. Indications for stenting
(i.e., “planned” versus “provisional” versus “urgent”) did not
differ between groups (Table 2). Before stent deployment,
patients with multivessel disease were treated slightly more
often with balloons and less often using ablative devices
(Table 2). Overall, the types of stents used and the average
number of stents per lesion were similar between groups
with most patients in both groups treated with the Palmaz-
Schatz stent (Table 2).
Lesion characteristics. Table 3 lists the lesion location
data for all stented lesions, and qualitative and quantitative
measurements available in 1,920 lesions. Multivessel stents
were implanted (1) more often in proximal segment, (2) less
often in an ostial location and (3) less often in restenotic
lesions (15% vs. 27%, p 5 0.001). By quantitative angiog-
raphy, the average pretreatment and posttreatment lesion
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
MI 5 myocardial infarction
Table 1. Baseline Characteristics of the Study Population
Vessels (Patients)
Single
(N 5 1,941)
Multivessel
(N 5 398) p Value
Characteristic
Mean age, yr 62 6 11 62 6 11 0.90
Male gender, % 71 73 0.42
Unstable angina, % 67 64 0.23
Hypertension, % 58 55 0.17
Diabetes mellitus, % 23 24 0.76
Hypercholesterolemia, % 67 68 0.84
Prior MI, % 51 47 0.18
Recent (#7 days) MI, % 16 11 0.003
Prior CABG, % 28 19 0.001
Prior angioplasty, % 48 39 0.001
LVEF, % 48 6 12 48 6 12 0.68
*LVEF 5 left ventricular ejection fraction.
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configurations and quantitative reference and lesion mea-
surements were similar for both groups, as well as the
angiographic procedural complications (Table 3).
Procedural results. Overall angiographic and procedural
success was high and similar for the two groups (Table 4).
Similarly, major in-hospital complications (death, Q-wave
MI and emergent CABG rates) were similar for both
groups (2.9% vs. 3.8%, p 5 0.14). Likewise, the prevalence
of periprocedural non–Q-wave MI (CK-MB $5 time
normal), repeat in-hospital target lesion angioplasty and
stent thrombosis was similar for the two groups. However,
CK-MB “leak” $3 times normal was more frequently
associated with multivessel stenting (23% vs. 18%, p 5
0.02). The periprocedural use of abciximab (ReoPro) was
similar for both groups (4.7% for single-vessel stenting
versus 6.1% for multivessel stenting, p 5 0.16). A represen-
tative case of two-vessel stenting is shown in Figure 1.
Long-term outcomes. Clinical follow-up was available in
1,836 of 1,941 patients (95%) with single-vessel interven-
tion and 378 of 398 patients (95%) with two- or three-vessel
intervention (Table 4). There was no difference in late
mortality (1.4% for one vessel vs. 0.7% for two or three
vessels, p 5 0.26). Interestingly, the rate of Q-wave MI was
lower for multivessel stenting versus single-vessel stenting
(0% vs. 1.2%, p 5 0.02). Overall target lesion revascular-
ization at 1 year was 16% for single-vessel intervention
versus 15% in multivessel intervention (p 5 0.38). Patients
with multivessel intervention more often underwent repeat
CABG (7.9% vs. 5.0%, p 5 0.002) and less often needed
repeat coronary angiopasty (6.8% vs. 11%, p 5 0.005). The
rate of any repeat revascularization was also similar for both
groups (20% for a single vessel vs. 21% for two or three
vessels, p 5 0.73). Likewise, actuarial event-free survival
curves for any cardiac event at follow-up (death, Q-wave
MI, angioplasty or CABG), was similar for both groups
(77% for one vessel vs. 78% for two or three vessels, p 5
0.52, Fig. 2).
Comparison to single-vessel disease. Of the patients,
1,549 of the 1,941 (80%) who underwent single-vessel
stenting had single-vessel coronary disease. A separate
analysis was performed to explore potential differences in
clinical outcomes for those patients compared with those
undergoing multivessel interventions. Major in-hospital
complications were similar for both groups (2.6% vs. 2.9%,
p 5 0.56). At follow up, there was no difference in death
(1.4% vs. 0.7%, p 5 0.25) or Q-wave MI (1.5% vs. 0%, p 5
Table 2. Interventional Procedures in Stented Lesions
Vessels (Lesions)
Single
(N 5 2,638)
Multivessel
(N 5 672)
p
Value
Stent indication 0.439
Planned, % 84 86
Provisional, % 8.0 7.5
Urgent, % 7.9 6.3
Procedure type (prestent)
Angioplasty (overall), % 97 100 0.001
Balloon angioplasty only, % 78 83 0.002
Rotational atherectomy, % 15 12 0.05
Excimer laser angioplasty, % 3.7 3.8 0.70
Directional atherectomy, % 3.3 1.2 0.003
Intravascular ultrasound, % 91 92 0.46
Type of stent
Coronary Palmaz-Schatz, % 71 69 0.26
Biliary Palmaz-(Schatz), % 6.2 11 0.001
Gianturco-Roubin-I, % 14 16 0.16
Gianturco-Roubin-II, % 6.2 4.2 0.05
NIR* 1.5 0.9 0.23
Multilink 0.6 0.1 0.04
$3 stents/vessel 3.8 3.1 0.85
No. of stents/vessel 1.3 6 0.6 1.2 6 0.5 0.67
Table 3. Qualitative and Quantitative Characteristics of
Stented Lesions
Vessels (Lesions)
Single
(N 5 2,638)
Multivessel
(N 5 672)
p
Value
Target vessel
Right coronary, % 41 40 0.67
Left anterior descending,
%
38 38 0.86
Left circumflex, % 21 22 0.76
Lesion location
Ostial, % 7.4 4.2 0.003
Proximal, % 40 45 0.02
Mid, % 39 41 0.52
Distal, % 12 9.2 0.03
Lesion characteristics (N 5 1,647) (N 5 273)
Restenotic, % 27 15 0.001
Calcium, % 36 33 0.48
Length, mm 11 11 0.76
Length $20 mm, % 12 12 0.98
Ulceration, % 10 10 0.92
Eccentricity, % 46 41 0.13
Thrombus, % 3.4 1.9 0.23
Bifurcation, % 6.1 5.4 0.69
Total occlusion, % 5.8 3.0 0.07
TIMI 0 or 1 5.8 3.0 0.07
Lesion class B2 or C 49 45 0.48
Procedural complications
Dissection $ type C, % 3.5 5.8 0.14
Abrupt closure, % 0.5 0 0.36
Perforation, % 0.1 0 0.65
Quantitative measurements
Proximal reference
MLD,* mm
3.12 6 0.5 3.10 6 0.6 0.83
Lesion MLD, mm
Preprocedure, mm 0.99 6 0.5 1.03 6 0.5 0.42
Poststent (final), mm 2.79 6 0.6 2.83 6 0.6 0.46
Lesion % diameter stenosis
Preprocedure, % 66 6 18 65 6 16 0.44
Poststent (final), % 8.2 6 15 5.9 6 15 0.10
*MLD 5 minimal lumen diameter.
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0.63) between groups (one vessel vs. multivessels, respec-
tively). Overall target lesion revascularization (16% vs. 15%,
p 5 0.47), any repeat revascularization (20% vs. 21%, p 5
0.46) and cardiac event-free survival (78% vs. 78%, p 5
0.89) were similar between groups (one vs. two- or three-
vessels).
Multivariate analysis. Logistic regression analysis was
used to identify independent predictors for cardiac events
(death, Q-wave MI, angioplasty or CABG), target lesion
revascularization and any repeat revascularization following
coronary stenting in native vessels (Table 5). Variables
included in the model were number of treated vessels,
number of stents implanted (1 or 2 vs. $3), unstable angina,
age, gender, previous coronary angioplasty, previous
CABG, diabetes mellitus, left ventricular ejection fraction,
proximal segment reference vessel diameter and final %
diameter stenosis. Unstable angina (1.39), diabetes (1.38),
history of CABG (1.37), previous coronary angioplasty
(1.63) and reference vessel diameter (0.77) were indepen-
dent predictors of cardiac event at follow up. Unstable
angina (1.26), diabetes mellitus (1.48), history of angio-
plasty (1.84) and reference vessel diameter (0.55) were
predictors of target lesion revascularization. The predictors
for any repeat revascularization were similar in addition to
prior CABG (1.38) (Table 5). The number of treated
vessels or stents was not an independent predictor for the
examined cardiac end points.
DISCUSSION
This study shows that patients undergoing nonstaged mul-
tivessel coronary intervention using stents in native coronary
arteries have (1) similar in-hospital procedural results and
major complications and (2) similar long-term (one year)
cardiac events, target lesion revascularization and any repeat
revascularization rates compared with single-vessel stent
interventions. In this large patient cohort, we also identified
independent predictors for subsequent cardiac events or
repeat revascularization following stent interventions; un-
stable angina, prior angioplasty or CABG, diabetes mellitus
and reference vessel diameter were associated with clinical
events in our multivariate model. Interestingly, the number
of vessels treated or stents used did not associate with
adverse cardiac end points. Those data are in accordance
with our recent publication, using multiple stents to treat
single coronary lesions (12). Thus, unlike previous nonstent
angioplasty experiences, stenting may be a viable therapeutic
alternative to CABG in carefully selected patients with
multivessel (i.e., primarily two-vessel) coronary disease.
Previous multivessel angioplasty experiences. Coronary
angioplasty or CABG has been indicated for the treatment
of multivessel coronary disease (13). The results of (non-
stent) multivessel angioplasty series showed variable proce-
dural success rates (82% to 95%), in-hospital mortality
(0.4% to 2.8%), MI (0.6% to 4.8%) and emergent CABG
(1.4% to 6.9%) (14–20). Long-term results were associated
with relatively high repeat revascularization rates (30% to
54%), and cardiac event-free survival was 64% to 74%
(14–20). Pooled data comparing coronary angioplasty with
CABG in patients with multivessel disease found equivalent
nonfatal MI and death rates at follow up (8). However,
patients undergoing multivessel angioplasty had signifi-
cantly more angina, repeat revascularization (mainly target
lesion revascularization) and worse quality of life compared
with CABG-treated counterparts (8). Moreover, according
to the Bypass Angioplasty Revascularization Investigation
(BARI) trial (21), diabetic patients with multivessel disease
had better survival when treated with surgery. This led to
the notion that coronary angioplasty may not be an optimal
therapy for multivessel disease primarily in patients with
diabetes mellitus (22). However, those studies did not
include “contemporary” angioplasty techniques in the
catheter-based treatment arms. Because no stent strategy
was available in those trials, the need for in-hospital CABG
was relatively high (5% to 10%), as well as the clinical
restenosis rates (37% to 55%) (14–20). Those results are less
favorable compared with our own experience and that of
others (23,24).
Multivessel stent experiences. Laham and colleagues (23)
reported the results of multivessel stenting in 103 patients
Table 4. In-hospital Procedural Results and Clinical Outcome
at One Year
Vessels (Patients)
Single
(N 5 1,941)
Multivessel
(N 5 398)
p
Value
In-hospital
Angiographic success, % 99 99 0.46
Procedural success, % 97 96 0.36
Death, % 0.6 0.5 0.31
Q-wave MI, % 0.7 0.9 0.65
Emergent CABG, % 1.6 0.5 0.08
Major hospital
complication
2.9 3.8 0.14
CK-MB $3 times
normal
18 23 0.02
Non–Q-wave MI 13 15 0.24
Stent thrombosis, % 0.9 0.5 0.35
Repeat angioplasty, % 1.6 0.7 0.16
One-year follow-up
Death, % 1.4 0.7 0.26
Q-wave MI, % 1.2 0 0.02
Target lesion
revascularization, %
16 15 0.38
Target lesion
angioplasty, %
11 6.8 0.002
Target lesion CABG, % 5.0 7.9 0.005
Any repeat
revascularization, %
20 21 0.73
Cardiac event-free
survival, %
77 78 0.52
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(212 vessels including saphenous vein grafts). Angiographic
success was achieved in 99%, mortality was 1% and Q-wave
and non–Q-wave MI rates were 2% and 11%. Importantly,
no patients required emergent CABG. The long-term (13
months) results showed mortality and MI in 4% each.
Target vessel revascularization was 17% (only 9% at the
stent site). Importantly, no patient required CABG at
follow-up and event-free survival was 79%.
Moussa and colleagues (24) reported the results of 100
patients undergoing multivessel coronary stenting with an-
giographic success achieved in 97% and hospital mortality of
1%. In-hospital CABG rate was 2%, Q-wave MI occurred
in 2% and non–Q-wave MI occurred in 6%. During follow
up, the mortality rate was 4%, the CABG was 2% and target
vessel revascularization was 30%.
Despite differences in patient demographics and method
of analysis between the studies, those single-center experi-
ences are consistent in showing favorable short- and long-
term results and particularly in comparison to “historical”
angioplasty experiences in multivessel disease. These results
altogether suggest that multivessel stenting in appropriately
selected patients may be a viable therapeutic strategy for
patients with multivessel coronary disease.
Non–Q-wave MI. In this study, there was relatively high
level of CK-MB elevation in both treated groups (one vs.
two or three vessels). When we used a threshold of $5 times
normal, there was no apparent difference between the study
groups (13% vs. 15%). However, when the threshold was set
at $3 times normal, a higher frequency of CK-MB “leak”
(23% vs. 18%) was found among patients with multivessel
interventions. This high prevalence of periprocedural “in-
termediate” CK-MB elevation probably reflects a cumula-
tive microembolization from multiple treated lesions into
larger myocardial territory. However, our preliminary long-
term experience did not indicate higher mortality, Q-wave
MI or repeat revascularization among patients with mul-
tivessel interventions despite their having higher prevalence
of procedural “intermediate” CK-MB rises. Also, based on
our data, late myocardial adverse coronary events after
Figure 1. A representative angiogram of a 47-year-old patient with unstable angina reveals two-vessel disease. The left anterior descending
lesions (arrows) were successfully treated using two overlapping stents. The right coronary artery angiogram showed a diffuse lesion
extending from the proximal to mid segment artery (arrows), successfully treated with three overlapping stents.
Figure 2. Actuarial event-free survival curves for any adverse event
(death, Q-wave MI, angioplasty or CABG, upper panel) up to 18
months following one-time percutaneous treatment of single
versus multivessel disease.
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stenting have been associated only with highest CK-MB
elevation ($5 normal) in native and saphenous vein graft
disease (25,26).
Limitations. Several limitations of our study should be
mentioned. First, this is a retrospective study rather than a
prospective randomized clinical trial designed to assess the
efficacy of stents in patients with multivessel disease. As
such, our patient cohort does not include patients with
multivessel disease who (a priori) were considered to be
better candidates for CABG. Those include patients with
diffuse three-vessel disease particularly with diffuse left
anterior descending involvement, patients with multiple
long (.20 mm) lesions and/or small-sized (,3.0 mm)
vessels, those with incessant restenosis or diffuse in-stent
restenosis in the context of multivessel disease and patients
with unsuccessful catheter-based revascularization ap-
proach. Also, it should be emphasized that the vast majority
of our patients underwent angioplasty in two (rather than
three) vessels. Therefore, the favorable results that we report
herein are not necessarily applicable for larger groups of
patients with three-vessel coronary disease. It should also be
indicated that patients in the single-vessel arm of the study
were much more likely to be part of protocols that mandated
follow-up angiography as a function of our heavy enroll-
ment into stent protocols. This would tend to increase the
detection of restenosis and naturally lead to higher revascu-
larization rates in the single-vessel arm of the study. Finally,
the current analysis does not include patients undergoing
multivessel stent intervention in saphenous vein grafts.
Because this patient population may differ in their baseline
demographics and clinical outcomes, we have elected to
address the issue of multivessel vein graft interventions in a
separate study.
Conclusions. Unlike previous conventional angioplasty ex-
periences, multivessel interventions using stents (primarily
in patients with two coronary intervention) have (1) similar
in-hospital procedural success and major complication rates,
and (2) similar long-term (one-year) clinical outcomes
compared with single-vessel stenting (death, MI and repeat
revascularization rates). Thus, multivessel coronary inter-
vention, using stents as indicated, does not confer incre-
mental procedural complications or repeat revascularization
risk compared with single-vessel treatment. Therefore,
stenting may be the preferred therapeutic strategy in care-
fully selected patient candidates with multivessel coronary
disease.
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